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Abstract
Background: Cardiovascular disease (CVD) is frequent in type 2 diabetes mellitus patients due to accelerated
atherosclerosis. Plasma osteoprotegerin (OPG) has evolved as a biomarker for CVD. We examined the relationship
between plasma OPG levels and different CVD manifestations in type 2 diabetes.
Methods: Type 2 diabetes patients without known CVD referred consecutively to a diabetes clinic for the first time
(n = 305, aged: 58.6 ± 11.3 years, diabetes duration: 4.5 ± 5.3 years) were screened for carotid arterial disease,
peripheral arterial disease, and myocardial ischemia by means of carotid artery ultrasonography, peripheral ankle
and toe systolic blood pressure measurements, and myocardial perfusion scintigraphy (MPS). In addition, plasma
OPG concentrations and other CVD-related markers were measured.
Results: The prevalence of carotid arterial disease, peripheral arterial disease, and myocardial ischemia was 42%,
15%, and 30%, respectively. Plasma OPG was significantly increased in patients with carotid and peripheral arterial
disease compared to patients without (p < 0.001, respectively), however, this was not the case for patients with
myocardial ischemia versus those without (p = 0.71). When adjusted for age, HbA1c and U-albumin creatinine ratio
in a multivariate logistic regression analysis, plasma OPG remained strongly associated with carotid arterial disease
(adjusted OR: 2.12; 95% CI: 1.22-3.67; p = 0.008), but not with peripheral arterial disease or myocardial ischemia.
Conclusions: Increased plasma OPG concentration is associated with carotid and peripheral arterial disease in
patients with type 2 diabetes, whereas no relation is observed with respect to myocardial ischemia on MPS. The
reason for this discrepancy is unknown.
Trial registration number: at http://www.clinicaltrial.gov: NCT00298844
Background
Cardiovascular disease (CVD) is the leading cause of
death in type 2 diabetes mellitus patients [1,2], as many
suffer from coronary heart disease, cerebrovascular dis-
ease, and/or peripheral arterial disease (PAD) [3-5].
Even, asymptomatic patients with type 2 diabetes display
subtle CVD [6-8], and therefore it has been debated if
screening for unknown CVD should be performed in
these patients [8].
Osteoprotegerin (OPG) is a soluble member of the
TNF-receptor superfamily and act as decoy receptor for
both the receptor activator of nuclear factor-B ligand
(RANK-L) and the TNF-related apoptosis inducing
ligand (TRAIL), two cytokines of the TNF-family [9].
OPG is found in bone, but also other mesenchymal tis-
sue, and the tissue concentration of OPG in aorta and
hip-bone are almost equal and approximately 500 times
higher than in plasma [10]. The function of OPG in the
arterial wall is not known, but it has been suggested
that the molecule acts as a vascular calcification inhibi-
tor due to the fact that OPG knock-out mice develop
arterial calcifications [11]. Interestingly, we have pre-
viously observed significantly higher concentrations of
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to non-diabetics [10]. During recent years, plasma OPG
has been attempted used as a biomarker for CVD, at
least in some populations [12]. The pathophysiological
connection between plasma OPG concentrations and
CVD is not known, but relations to both arterial disease
as well as to diseased myocardium has been suggested
[13,14].
To investigate the relationship between plasma OPG
levels and CVD manifestations in type 2 diabetes, all
patients were screened for carotid arterial disease, per-
ipheral arterial disease, and myocardial ischemia. Subse-
quently, we assessed the relationship between these
CVD manifestations and plasma OPG.
Methods
Patient cohort
We consecutively evaluated all 753 type 2 diabetes
patients referred to the Diabetes Clinic at Odense Uni-
versity Hospital, Denmark, from January 2006 to
December 2007 of which 305 patients met the inclusion
and exclusion criteria as previously reported [15]. The
diagnosis of type 2 diabetes was made by each patient’s
general practitioner using the WHO criteria [16].
The study was carried out according to Good Clinical
Practice, followed the Helsinki II Declaration, was
approved by the Local Ethics Committee, and registered
at http://www.clinicaltrials.gov. All participants gave
written, informed consent.
All patients went through a single-day structured
examination program including medical history record-
ing and a cardiovascular risk factor evaluation. Physical
and laboratory examinations were done and fasting blood
samples were obtained for laboratory testing. Finally,
patients were screened for CVD in the three vascular ter-
ritories, i.e., for carotid vessel wall changes using B-mode
ultrasound, for PAD using ankle and toe systolic blood
pressure measurements, and for myocardial ischemia
using myocardial perfusion scintigraphy (MPS).
Laboratory analyses
Plasma osteoprotegerin concentrations were measured
in EDTA-plasma using an immunoassay based on a
commercially available sandwich ELISA (R&D Systems,
Minneapolis, MN, USA) with specific antibodies against
human OPG and europium-labeled streptavidin for
detection. Bound europium was measured by time-
resolved fluorometric detection using an Autodelfia
Instrument from Perkin Elmer/Wallac (Turku, Finland).
The analytical range was 62.5-20000 ng/l with an intra-
assay imprecision of 4% and an inter-assay imprecision
of 7%.
HbA1c was measured by cation-exchange chromato-
graphy using Tosoh G7 (Medinor, Broendby, Denmark)
with dedicated reagents. Glucose, total cholesterol, LDL
cholesterol, HDL cholesterol, and high-sensitive CRP
were all analyzed on a Modular Analytics P (Roche
Diagnostics, Switzerland) with methods applied as
recommended by the supplier.
I nam o r n i n gs p o tu r i n es a m p l eU - a l b u m i nw a sm e a -
sured using immunoturbidimetry (Roche, Basel, Switzer-
land). The discrimination limit for U-albumin was < 10
mg/l. In the case of U-albumin < 10 mg/l the U-albumin
creatinine ratio was set to 0.
B-mode ultrasound scans of the carotid artery
The B-mode ultrasound scans of the carotid arteries
were performed using a Vivid-5 GE medical ultrasound
machine (10-MHz linear transducer) and continuous
ECG recording during the procedure. The carotid
intima-media thickness (CIMT) was measured semi-
automatically as the mean of minimum 200 measure-
ments of CIMT per location site from digitally stored
images. CIMT was measured bilaterally at the posterior
wall (at the bulbus region and at the proximal end of
the common carotid artery), using two independent
images at end-diastole. Each image was also investigated
for plaques using the ARIC-study plaque definition [17].
Carotid arterial disease was defined as mean CIMT >
1.00 mm [18] and/or the presence of a plaque at any
carotid location. The limits of agreement between two
observers (AJ, MKP) in 20 randomly selected patients
on mean CIMT was: average = 0.039 ± 0.061 mm (95%
limits of agreement: -0.158-0.081). The absolute interob-
server agreement on plaques was 98% (kappa: 0.74).
Ankle and toe systolic blood pressure measurements
Ankle and toe systolic blood pressure measurements
were performed using the strain gauge technique [19].
All subjects rested for 20 min. in the supine position
before cuffs were placed around the ankles (cuff width:
12.0 cm) and proximal phalanges of the big toe (cuff
width: 2.5 cm). Strain gauges were placed around the
distal phalanges of the big toe. Duplicate measurements
of ankle and toe systolic blood pressures were obtained.
Arm systolic and diastolic blood pressures were mea-
sured. The ankle-brachial index (ABI) and the toe systo-
lic blood pressure index (TSPI) were calculated as the
systolic blood pressure at each level, respectively,
divided by the arm systolic blood pressure. PAD was
defined as ABI < 0.90 and/or TSPI < 0.64.
Myocardial perfusion scintigraphy
Myocardial perfusion scintigraphy (MPS) examinations
were performed using stress ECG-gated
99 mtechnetium
MPS according to standards of the American Society of
Nuclear Cardiology using ECG-gated single photon
emission computed tomography [20]. The MPS protocol
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viously [15]. In brief, whenever a potential stress-
induced perfusion defect was observed, an additional
rest study was carried out to evaluate the degree of
reversibility. A semi-quantitative visual interpretation
was made by means of short axis, horizontal-, and verti-
cal long axis myocardial tomograms and a 20-segment
model. All images were analyzed by two experts (AJ,
PFHC) blinded to all other data and each other, and a
summed stress score (SSS) was calculated. Myocardial
ischemia was defined as a regional perfusion abnormal-
ity with a total SSS ≥ 4 and at least one segment having
a SSS ≥ 2 [15].
Statistics
Continuous variables are presented as mean and stan-
dard deviations and categorical variables as numbers,
and percentages with 95% confidence intervals (CI). Stu-
dent’s t-test was used to test for differences between
independent continuous variables. Due to a non-Gaus-
sian distribution of U-albumin creatinine ratio, hs-CRP
and plasma OPG, these parameters are presented as
median and interquartile range, and the Mann-Whitney
test was used to compare groups. The c
2-test was used
to test for differences between categorical variables. Uni-
variate and multivariate logistic regression analysis were
performed, using carotid arterial disease, peripheral
arterial disease, and myocardial ischemia as separate
outcome variables. The co-variables were adjusted for
age, HbA1c and U-albumin creatinine ratio. Results are
reported as odds ratio (OR) with 95% CI and p-values.
A p-value < 0.05 was considered statistically significant.
STATA version 9.2 was used for calculations.
Results
Characteristics of the patients are presented in Table 1.
T h ep r e v a l e n c eo fC V Di nt h ep r e s e n ts t u d yh a sb e e n
published previously [15].
The plasma OPG concentrations were significantly
increased in patients with carotid arterial disease and
PAD compared to patients without (1.28 (0.99-1.61) ver-
sus 1.04 (0.80-1.33) μg/l, p < 0.001 and 1.47 (1.02-1.89)
versus 1.08 (0.85-1.40) μg/l, p < 0.001, respectively)
(Table 2 and Figure 1). However, this was not the case
for patients with myocardial ischemia versus those with-
out myocardial ischemia (1.11 (0.87-1.55) versus 1.11
(0.89-1.43) μg/l, p = 0.711) (Table 2 and Figure 1).
Furthermore, the upper quartile of plasma OPG and
myocardial ischemia were tested in a univariate logistic
regression analysis and did not show any relationship
(OR: 1.46; 95% CI: 0.85-2.53; p = 0.172). CIMT was cor-
related with plasma OPG concentrations in a simple lin-
ear correlation analysis (r = 0.249; p < 0.001). Plasma
OPG concentrations were associated with carotid
arterial disease in both univariate and multivariate logis-
tic regression analysis when adjusted for age, HbA1c
and U-albumin creatinine ratio (adjusted OR: 2.12; 95%
CI: 1.22-3.67; p = 0.008), but not peripheral arterial dis-
ease or myocardial ischemia (adjusted OR: 1.77; 95% CI:
0.97-3.22; p = 0.063 or adjusted OR: 1.26; 95% CI: 0.77-
2.06; p = 0.364, respectively) (Table 3). Systolic blood
pressure was significantly increased in patients with car-
otid arterial disease compared to those without (141 ±
17 versus 137 ± 19 mmHg, p = 0.028). However, systolic
blood pressure was not significantly different in patients
with or without PAD or myocardial ischemia, respec-
tively. Further diastolic blood pressure was significantly
increased in patients with PAD compared to those with-
out (80 ± 11 versus 76 ± 11 mmHg, p = 0.033). Diasto-
lic blood pressure was on the other hand not different
in patients with or without carotid arterial disease or
myocardial ischemia, respectively (Table 2). In the mul-
tivariate logistic regression analysis only systolic blood
pressures was associated with carotid arterial disease,
but not with PAD or myocardial ischemia, respectively
(Table 3). HbA1c and U-albumin creatinine ratio were
not significantly differently in patients with or without
carotid arterial disease, PAD or myocardial ischemia,
respectively (Table 2). Finally, total cholesterol, LDL
cholesterol, HDL cholesterol, triglyceride and high-sensi-
tive C-reactive protein (hs-CRP) concentrations were
not significantly different or associated with carotid
arterial disease, PAD, or myocardial ischemia, respec-
tively (Table 2 and 3).
Discussion
The present study demonstrated in a large population of
type 2 diabetes patients with no history of cardiovascu-
lar disease and relative short diabetes duration that
plasma OPG levels were significantly increased in those
with carotid arterial disease and PAD compared to
patients without these manifestations. This was, how-
ever, not the case for patients with subtle signs of myo-
cardial ischemia versus those without. When adjusted
for age, HbA1c and U-albumin creatinine ratio in a
multivariate logistic regression analysis, plasma OPG
levels was associated with carotid arterial disease, but
not with PAD or myocardial ischemia.
OPG is an important regulating molecule in bone
turnover, and plasma OPG has been shown to correlate
to bone and arterial diseases [21]. Of note, plasma OPG
has been demonstrated to be an independent risk factor
for the 10-year incidence of CVD and vascular mortality
[22]. In diabetes mellitus, accumulation of OPG may be
part of the generalized matrix changes seen in the arter-
ial wall [9,23], which could relate to the fact that pro-
duction of OPG from vascular smooth muscle cells is
highly influenced by pro-inflammatory and hormonal
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study found higher plasma OPG concentrations in dia-
betes individuals compared with non-diabetics, although
the absolute concentration difference was limited [21].
Therefore, it was highly relevant to investigate any
relation between different CVD manifestations in type 2
diabetes patients and plasma OPG.
Our findings are compatible with the study by
Ishiyama et al., who found that CIMT was positively
correlated to plasma OPG levels in patients with type 2
Table 1 Characteristics of the type 2 diabetes patients
Total CVD by examination No CVD by examination
(n = 305) (n = 183) (n = 122)
Females/males 139/166 77/106 62/60
Age (years) 58.6 ± 11.3 60.7 ± 11.1 †† 55.3 ± 11.0
Diabetes duration (years) 4.5 ± 5.3 4.7 ± 5.5 4.1 ± 4.9
BMI (kg/m
2) 32.2 ± 5.8 32.3 ± 6.3 32.2 ± 5.0
Waist circumference (cm) 107.9 ± 14.3 108.2 ± 15.0 107.5 ± 13.1
Hip circumference (cm) 110.2 ± 11.5 110.3 ± 12.3 110.2 ± 10.2
Blood pressure, systolic (mmHg) 138.7 ± 18.1 140.1 ± 17.0 136.6 ± 19.6
Blood pressure, diastolic (mmHg) 79.5 ± 10.9 79.3 ± 10.4 79.8 ± 11.7
Antidiabetic medical treatment
No antidiabetic treatment 65 (21) 40 (22) 25 (20)
Metformine 189 (62) 107 (58) 82 (67)
Rosiglitazone 19 (6) 14 (8) 5 (4)
DPP-IV-inhibitor 5 (2) 4 (2) 1 (1)
Sulphonylurea 76 (25) 46 (25) 30 (25)
Insulin 73 (24) 46 (25) 27 (22)
Blood samples/urine samples
Fasting p-glucose (mmol/l) 8.6 ± 2.5 8.8 ± 2.5 8.4 ± 2.4
HbA1c (%) 7.3 ± 1.3 7.5 ± 1.3 † 7.1 ± 1.2
Fasting C-peptide (pmol/l) 1146 ± 644 1169 ± 688 1112 ± 573
Fasting insulin (pmol/l) 106 ± 104 112 ± 119 96 ± 77
Total cholesterol conc. (mmol/l) 4.4 ± 1.0 4.4 ± 1.1 4.3 ± 0.9
LDL-cholesterol conc. (mmol/l) 2.2 ± 0.8 2.2 ± 0.9 2.1 ± 0.7
HDL-cholesterol conc. (mmol/l) 1.28 ± 0.34 1.29 ± 0.34 1.26 ± 0.35
Triglycerides (mmol/l) 2.07 ± 1.29 2.06 ± 1.31 2.09 ± 1.27
Creatinine (μmol/l) 90 ± 24 91 ± 24 88 ± 25
U-albumin creatinine ratio (mg/mmol)* 0.8 (0.0-3.5) 0.8 (0.0-3.1) 0.8 (0.0-3.8)
Hs-CRP (mg/l)* 2.9 (1.4-6.9) 3.0 (1.3-6.8) 2.8 (1.6-7.2)
Osteoprotegerin (μg/l)* 1.11 (0.88-1.46) 1.22 (0.94-1.54) †† 1.05 (0.78-1.24)
Risk factors for CVD
Family history of CVD
# 58 (19) 31 (17) 26 (21)
Hypertension
## 197 (64) 124 (68) 72 (59)
Hypercholesterolemia
## 193 (63) 113 (62) 80 (66)
Current smoker 82 (27) 49 (27) 32 (26)
Angina pectoris
None 236 (77) 139 (76) 97 (80)
Non-cardiac chest pain 40 (13) 24 (13) 16 (13)
Atypical angina pectoris 17 (6) 11 (6) 6 (5)
Typical angina pectoris 12 (4) 9 (5) 3 (2)
Data are means ± SD, (*median (interquartile range)) or n (%). CVD by examination = cardiovascular disease obtained from B-mode ultrasound scans of the carotid
arteries, ankle and toe systolic blood pressure measurements and/or myocardial perfusion scintigraphy.
Patients with CVD vs. without CVD by examination: † = p < 0.05. †† = p < 0.01.
DDP-IV-inhibitor = Dipeptidyl peptidase IV inhibitor treatment. See text for definitions.
#A positive family history of cardiovascular disease defined as cardiovascular disease either in male first-degree relative < 55 years or in female first-degree relative < 65
years.
##A medical history of hypertension or hypercholesterolemia, respectively.
* tested with the Mann-Whitney nonparametric test.
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the presence of carotid plaques [22] or increased CIMT
[25], is well correlated to plasma OPG levels in healthy
individuals. Altogether, we therefore find that the rela-
tion between plasma OPG and carotid arterial disease in
type 2 diabetes patients is well-established. Of note, it
has recently been published that CIMT can be deter-
mined with good and comparable reproducibility in type
2 diabetes patients as well as in non-diabetics [26].
Few studies have investigated the relation between
PAD and plasma OPG levels. In these investigations
PAD was associated with plasma OPG [27], but no
study has, up till now, investigated the relationship
between PAD and plasma OPG in type 2 diabetes
patients. In the present study, we observed that plasma
OPG was significantly increased in patients with PAD
compared to patients without (Figure 1). Further,
plasma OPG was associated with PAD in our type 2 dia-
betes patients in univariate logistic regression analysis,
but not after adjusting for age, HbA1c and U-albumin
creatinine ratio. The association between plasma OPG
levels and both carotid arterial disease and PAD, respec-
tively, expand earlier observations between plasma OPG
and macrovascular disease [28].
The relationship between plasma OPG concentrations
and signs of myocardial ischemia on MPS in patients
with type 2 diabetes has previously been investigated by
Avignon et al. Our data could, however not demonstrate
Table 2 Comparison of risk factors of cardiovascular disease and different cardiovascular disease manifestations
Carotid arterial disease No carotid arterial disease
Co-variables (n = 129) (n = 176) p
Blood pressure, systolic (mmHg) 137 ± 19 141 ± 17 0.028
Blood pressure, diastolic (mmHg) 80 ± 11 79 ± 11 0.649
HbA1c (%) 7.3 ± 1.2 7.3 ± 1.3 0.851
U-albumin creatinine ratio (mg/mmol)* 0.6 (0.0-2.8) 1.0 (0.0-4.3) 0.467
Total cholesterol (mmol/l) 4.4 ± 1.2 4.4 ± 0.9 0.861
LDL cholesterol (mmol/l) 2.2 ± 0.9 2.2 ± 0.8 0.930
HDL cholesterol (mmol/l) 1.31 ± 0.36 1.26 ± 0.33 0.193
Triglycerides (mmol/l) 1.97 ± 0.11 2.15 ± 0.10 0.236
Hs-CRP (mg/l)* 2.6 (1.3-6.3) 3.0 (1.7-7.5) 0.306
Osteoprotegerin (μg/l)* 1.28 (0.99-1.61) 1.04 (0.80-1.33) < 0.001
Peripheral arterial disease No peripheral arterial disease
Co-variables (n = 45) (n = 260) P
Blood pressure, systolic (mmHg) 138 ± 18 143 ± 19 0.064
Blood pressure, diastolic (mmHg) 80 ± 11 76 ± 11 0.033
HbA1c (%) 7.3 ± 1.3 7.6 ± 1.2 0.084
U-albumin creatinine ratio (mg/mmol)* 0.6 (0.0-19.9) 0.8 (0.0-3.0) 0.098
Total cholesterol (mmol/l) 4.4 ± 1.2 4.4 ± 1.0 0.930
LDL cholesterol (mmol/l) 2.1 ± 0.9 2.2 ± 0.8 0.930
HDL cholesterol (mmol/l) 1.34 ± 0.41 1.27 ± 0.33 0.195
Triglycerides (mmol/l) 2.09 ± 1.47 2.07 ± 1.26 0.926
Hs-CRP (mg/l)* 3.5 (1.4-7.5) 2.8 (1.4-6.9) 0.607
Osteoprotegerin (μg/l)* 1.47 (1.02-1.89) 1.08 (0.85-1.40) < 0.001
Myocardial ischemia No myocardial ischemia
Co-variables (n = 92) (n = 213) p
Blood pressure, systolic (mmHg) 141 ± 18 138 ± 18 0.117
Blood pressure, diastolic (mmHg) 81 ± 9 79 ± 11 0.164
HbA1c (%) 7.5 ± 1.4 7.2 ± 1.2 0.064
U-albumin creatinine ratio (mg/mmol)* 1.1 (0.0-4.0) 0.6 (0.0-3.3) 0.435
Total cholesterol (mmol/l) 4.3 ± 1.0 4.4 ± 1.0 0.750
LDL cholesterol (mmol/l) 2.2 ± 0.8 2.2 ± 0.8 0.931
HDL cholesterol (mmol/l) 1.23 ± 0.32 1.30 ± 0.35 0.118
Triglycerides (mmol/l) 2.09 ± 1.14 2.07 ± 1.36 0.924
Hs-CRP (mg/l)* 4.1 (1.3-7.4) 2.8 (1.5-6.4) 0.419
Osteoprotegerin (μg/l)* 1.11 (0.87-1.55) 1.11 (0.89-1.43) 0.711
Data are means ± SD or median (interquartile range). * tested with the Mann-Whitney nonparametric test.
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strated that myocardial ischemia was associated with the
upper quartile of plasma OPG levels [6], however, when
comparing the two studies, they differ in at least five
important ways, as 1) Avignon et al. included patients
with two or more risk factors of CVD, whereas we had
no exclusion criteria regarding the number of risk fac-
tors, 2) they included patients with known PAD (10%),
whereas these were excluded in our study, 3) they
included type 1 diabetes patients (24%) as well as type 2
diabetes patients (76%), whereas we exclusively included
patients with type 2 diabetes, 4) the duration of diabetes
was almost four times longer in their population com-
pared to ours, and 5) finally they did not examine for
carotid or peripheral arterial disease as we did. In con-
clusion, the patients in the study by Avignon et al.
would properly have a higher a priori burden of athero-
sclerosis, which could to some extend explain why we
could not find the same relation between myocardial
ischemia and plasma OPG levels in our population of
exclusive type 2 diabetes patients. The reason for the
lack of relationship between myocardial ischemia on
MPS and plasma OPG could be caused by the fact that
MPS-results reflect relative flow differences in the cor-
onary vessels, which can be decreased by either epicor-
onary artery stenosis or microvascular coronary disease.
The epicoronary artery stenosis is caused by athero-
sclerosis, which is shown to correlate well with plasma
OPG levels in type 2 diabetes [9]. However, microvascu-
lar coronary disease could be caused by endothelial dys-
function, something that is observed more frequently in
type 2 diabetes patients both with and without coronary
artery disease [29], and therefore from a theoretically
point of view this should have no direct relationship to
plasma OPG levels. For this reason, MPS could be con-
sider as a less optimal investigation technique when
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Figure 1 Plasma osteoprotegerin in patients with and without carotid or peripheral arterial disease or myocardial ischemia. OPG =
osteoprotegerin. CAD = carotid arterial disease. PAD = peripheral arterial disease. MI = myocardial ischemia on MPS.
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however, MPS was the only noninvasive technique avail-
able at the time, and we could not from a clinical point
of view justify investigating our patients invasively.
A recent study by Altinova et al. investigated 166 con-
secutively enrolled type 2 diabetes patients, and found
that plasma OPG was associated with age, glycemic con-
trol and microalbuminuria [30]. The study, however, did
not state the number of patients with already known
cardiovascular disease. Further the study did not exam-
ine each patient for cardiovascular disease in the three
arterial vascular territories, where cardiovascular disease
is often encountered, i.e., the coronary, carotid, and
lower-extremity arteries. Other studies in type 2 diabetes
patients have found that cardiovascular events were
individually associated with increased age, dysregulated
diabetes or microalbuminuria [31,32]. Therefore it
seems reasonable that type 2 diabetes patients with
increased age, dysregulated diabetes or microalbumi-
nuria would have increased cardiovascular disease and
therefore increased OPG levels compared with younger,
well-controlled type 2 diabetes patients without microal-
buminuria. For these reasons it is difficult to conclude
from the study by Altinova et al. if plasma OPG levels
were associated with diabetes related parameters (i.e.
HbA1c and microalbuminuria) or these associations
really were due to atherosclerosis [30]. In our study we
found that plasma OPG was independently associated
with carotid arterial disease when adjusting for age,
HbA1c, and U-albumin creatinine ratio (adjusted OR:
Table 3 Association between risk factors of cardiovascular disease and different cardiovascular disease manifestations
Carotid arterial disease
Co-variables Univariate Multivariate*
Odds ratio 95% CI p Odds ratio 95% CI P
Blood pressure, systolic (mmHg) 1.01 1.00-1.03 0.030 1.01 1.00-1.03 0.102
Blood pressure, diastolic (mmHg) 1.00 0.97-1.02 0.648 1.00 0.99-1.03 0.391
Total cholesterol (mmol/l) 0.98 0.79-1.22 0.861 1.00 0.79-1.26 0.998
LDL cholesterol (mmol/l) 1.01 0.77-1.33 0.930 1.07 0.80-1.44 0.627
HDL cholesterol (mmol/l) 1.55 0.80-3.02 0.195 0.81 0.38-1.72 0.590
Triclycerides (mmol/l) 0.89 0.74-1.08 0.238 0.97 0.80-1.18 0.741
Hs-CRP (mg/l) 1.00 0.97-1.03 0.890 1.00 0.97-1.03 0.827
Osteoprotegerin (μg/l) 3.37 2.02-5.65 < 0.001 2.12 1.22-3.67 0.008
Peripheral arterial disease
Co-variables Univariate Multivariate*
Odds ratio 95% CI p Odds ratio 95% CI P
Blood pressure, systolic (mmHg) 1.02 0.99-1.03 0.066 1.01 0.99-1.03 0.237
Blood pressure, diastolic (mmHg) 0.97 0.93-1.00 0.033 0.97 0.94-1.00 0.058
Total cholesterol (mmol/l) 0.99 0.72-1.34 0.929 0.99 0.72-1.35 0.935
LDL cholesterol (mmol/l) 0.85 0.57-1.27 0.420 0.86 0.58-1.28 0.454
HDL cholesterol (mmol/l) 1.76 0.75-4.16 0.197 1.29 0.48-3.44 0.617
Triclycerides (mmol/l) 1.01 0.79-1.29 0.926 1.08 0.84-1.39 0.552
Hs-CRP (mg/l) 1.01 0.97-1.05 0.578 1.01 0.97-1.04 0.746
Osteoprotegerin (μg/l) 2.78 1.65-4.68 < 0.001 1.77 0.97-3.22 0.063
Myocardial ischemia
Co-variables Univariate Multivariate*
Odds ratio 95% CI p Odds ratio 95% CI P
Blood pressure, systolic (mmHg) 1.01 0.99-1.02 0.119 1.01 1.00-1.03 0.132
Blood pressure, diastolic (mmHg) 1.02 0.99-1.04 0.166 1.01 0.99-1.03 0.395
Total cholesterol (mmol/l) 0.96 0.76-1.22 0.749 0.96 0.75-1.22 0.714
LDL cholesterol (mmol/l) 1.01 0.75-1.36 0.931 1.01 0.75-1.36 0.960
HDL cholesterol (mmol/l) 0.54 0.25-1.17 0.119 0.65 0.29-1.48 0.306
Triclycerides (mmol/l) 1.01 0.84-1.22 0.924 0.97 0.80-1.18 0.749
Hs-CRP (mg/l) 1.02 0.99-1.05 0.256 1.02 0.99-1.05 0.289
Osteoprotegerin (μg/l) 1.13 0.73-1.77 0.584 1.26 0.77-2.06 0.364
Data are odds ratios, 95% confidence intervals (CI), and p-values. The outcome variables are carotid arterial disease, peripheral arterial disease, and myocardial
ischemia, respectively.
*Adjusted for age, HbA1c and U-albumin-creatinine ratio.
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Page 7 of 92.12; 95% CI: 1.22-3.67; p = 0.008). Whereas peripheral
arterial disease and myocardial ischemia were not when
adjusting for the above mentioned parameters (adjusted
OR: 1.77; 95% CI: 0.97-3.22; p = 0.063 and adjusted OR:
1.26; 95% CI: 0.77-2.06; p = 0.364). The reason for this
could be that plama OPG levels were both associated to
diabetes related parameters (i.e. HbA1c and U-albumin
creatinine ratio) as well as to atherosclerotic related
parameters (i.e. carotid arterial disease).
Our finding of associations between plasma OPG and
atherosclerotic disease manifestations in type 2 diabetes
is in agreement with the notion that this molecule may
be involved in atherogenesis. The precise role of OPG
in atherogenesis is unknown, however one suggestion is
that the molecule function as a calcification inhibitor
[11]. It is present in atherosclerotic plaques, particularly
in areas with calcification [33], and may be compensa-
tory upregulated in the atherogenic process. Other pos-
sible connections to atherosclerosis may, however also
occur, since OPG has been shown to enhance the
matrix content in plaques [34], and to be involved in
endothelial function [35].
Limitations
The present study has some potential limitations: 126
out of 431 eligible patients refused to participate or did
not show up. However, no statistical differences were
present between the study group and the non-partici-
pants with regard to age and diabetes duration (age:
58.6 ± 11.3 versus 60.7 ± 14.7 years, p = 0.15 and dia-
betes duration: 4.5 ± 5.3 versus 4.0 ± 6.5 years, p =
0.51). We did not test for other differences and, hence,
selection bias cannot be totally excluded.
Conclusions
In a consecutive series of type 2 diabetes patients without
known or suspected CVD referred to a diabetes clinic for
the first time with less than five years’ average diabetes
duration the present study found that plasma OPG levels
were associated with the presence of carotid and peripheral
arterial disease. Further, plasma OPG levels were not related
to myocardial ischemia on MPS. When adjusting for age,
HbA1c and U-albumin creatinine ratio plasma OPG levels
were only associated with carotid arterial disease.
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